A phase III international, multi-center, prospective, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of nitric oxide synthase inhibition with tilarginine acetate injection in patients with cardiogenic shock complicating acute myocardial infarction, or the TRIUMPH trial
Phase of Trial: Phase III
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Tilarginine (Primary)
- Indications Cardiogenic shock; Myocardial infarction
- Focus Therapeutic Use
- Acronyms TRIUMPH
- 28 Mar 2007 Results have been published.
- 23 Oct 2005 New trial record.